<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="289">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044264</url>
  </required_header>
  <id_info>
    <org_study_id>DAC-501-601-727998</org_study_id>
    <nct_id>NCT01044264</nct_id>
    <nct_alias>NCT00807638</nct_alias>
  </id_info>
  <brief_title>Clinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations</brief_title>
  <official_title>A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled Study Comparing Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations in the Treatment of Moderate to Severe Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perrigo Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perrigo Company</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, multiple-site, placebo-controlled, parallel-group clinical study
      conducted to evaluate the bioequivalence of two 1% Clindamycin/5% Benzoyl Peroxide Topical
      Gel formulations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction of Inflammatory Lesions</measure>
    <time_frame>Baseline and week 11</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint of the study was the mean percent reduction from baseline to week 11 in inflamed lesion count (papules and pustules).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">602</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>1% Clindamycin/5% Benzoyl Peroxide Topical Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Test product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Clindamycin/5% Benzoyl Peroxide Topical Gel</intervention_name>
    <description>Topical Gel</description>
    <arm_group_label>1% Clindamycin/5% Benzoyl Peroxide Topical Gel</arm_group_label>
    <arm_group_label>DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel</arm_group_label>
    <other_name>DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy men or women, 12 years of age and older

          -  willing to participate and sign a copy of the informed consent form

          -  moderate to severe facial acne

        Exclusion Criteria:

          -  history of allergy or hypersensitivity to clindamycin or benzoyl peroxide

          -  pregnant or lactating women

          -  evidence of a clinically significant disorder

          -  receipt of any drugs as part of a research study within 30 days prior to study dosing

          -  use of systemic, topical or facial products which may interfere with study

          -  significant facial hair, tattoos, excessive facial scarring, active facial sunburn,
             or peeling due to sunburn
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 17, 2013</lastchanged_date>
  <firstreceived_date>January 4, 2010</firstreceived_date>
  <firstreceived_results_date>September 14, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <keyword>bioequivalency</keyword>
  <keyword>clindamycin</keyword>
  <keyword>benzoyl peroxide</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
